SARS-CoV-2 Neutralizing Antibody Standard

USA

-20°C

The product is specific for SARS-CoV-2 RBD domain.

Recombinant SARS-CoV-2 RBD Protein

Protein A affinity column

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease in 2019 (COVID-19). SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells.Neutralizing antibodies against SARS-CoV-2 can block the interaction between SARS-CoV-2 RBD and ACE2. The blocking ability of SARS-CoV-2 neutralizing antibodies is affected by its quantity. This standard product is intended for the calibration of SARS-CoV-2 neutralizing antibodies in the materials or samples. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 neutralizing antibodies. The neutralizing antibody standard binds to multiple neutralizing epitopes in the receptor-binding domain. This product has been verified to calibrate the quantitative assay of SARS-CoV-2 neutralizing antibody with the Surrogate Virus Neutralization Test (sVNT) (GenScript, Cat.No L00847-A), plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT) (GenScript, Cat.No SC2087). Users can design assays to detect and evaluate the quantitation of SARS-CoV-2 neutralizing antibodies by this product.